Epidermal growth factor receptor expression in neurofibromatosis type 1- related tumors and NF1 animal models

Journal of Clinical Investigation

Volumn 105, Issue 9, 2000, Pages 1233-1241

  DeClue, Jeffrey E ^a   Heffelfinger, Sue ^b   Benvenuto, Giovanna ^a,d   Ling, Bo ^b   Li, Shaowei ^a   Rui, Wen ^b   Vass, William C ^a   Viskochil, David ^c   Ratner, Nancy ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; EMBRYO; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NERVE SHEATH TUMOR; NEUROFIBROMA; NEUROFIBROMATOSIS; NONHUMAN; NORTHERN BLOTTING; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHWANN CELL;

EID: 0034102193     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI7610     Document Type: Article

References (46)

1. Huson, S.M., Harper, P.S., and Compston, D. 1988. Von Recklinghausen neurofibromatosis: a clinical and population study in south-east Wales. Brain. 111:1355-1381.
2. Upadhyaya, M., and Cooper, D.N. 1998. Neurofibromatosis type 1: from genotype to phenotype. BIOS Scientific Publishers Ltd. Oxford, United Kingdom, pp. 230.
3. Ferner, R.E. 1998. Clinical aspects of neurofibromatosis I. In Neurofibromatosis type 1: from genotype to phenotype. M. Upadhyaya and D.N. Cooper, editors. BIOS Scientific Publishers Ltd., Oxford, United Kingdom. 21-38.
4. Rosenbaum, T., Petrie, K.M., and Ratner, N. 1997. Neurofibromatosis type 1: genetic and cellular mechanisms of peripheral nerve tumor formation. The Neuroscientist. 3:412-420.
5. Stefansson, K., Wollmann, R., and Jerkovic, M. 1982. S-100 protein in soft tissue tumours derived trom Schwann cells and melanocytes. Am. J. Pathol. 106:261-268.
6. Peltonen, J., et al. 1988. Cellular differentiation and expression of matrix genes in type 1 neurofibromarosis. Lab. Invest. 59:760-761.
7. Sheela, S., Riccardi, V.M., and Ratner, N. 1990. Angiogenic and invasive properties of neurofibroma Schwann cells. J. Cells Biol. 111:645-653.
8. Ducatman, B.S., Scheithauer, B.W., Piepgras, D.G., and Reiman, H.M. 1984. Malignant peripheral nerve sheath tumors in childhood. J. Neurooncol. 2:241-248.
9. Zoller, M.E., Rembeck, B., Oden, A., Samuelsson, M., and Angervall, L. 1997. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer. 79:2125-2131.
10. Side, L.E., and Shannon, K.M. 1998. The NF1 gene as a tumor suppressor. In Neurofibromatosis type 1: from genotype to phenotype. M. Upadhyaya and D.N. Cooper, editors. BIOS Scientific Publishers Ltd. Oxford, United Kingdom, 133-152.
11. Morioka, N., Tsuchida, T., Etoh, T., Ishibashi, Y., and Otsuka, F. 1990. A case of neurofibrosarcoma associated with neurofibromatosis light microscopic ultrastructural, immunohistochemical and biochemical investigations. J. Dermatol. 17:312-316.
12. Wallace, M.R., et al. 1990. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 249:181-186.
13. Cawthon, R., et al. 1990. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 62:193-201.
14. Viskochil, D., et al. 1990. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell. 62:187-192.
15. Upadhyaya, M., and Cooper, D.N. 1998. The mutational spectrum in neurofibromatosis 1 and its underlying mechanisms. In Neurofibromatosis type 1: from genotype to phenotype. M. Upadhyaya and D.N. Cooper, editors. BIOS Scientific Publishers Ltd. Oxford, United Kingdom, 65-88.
16. Boguski, M.S., and McCormick, F. 1993. Proteins regulating Ras and its relatives. Nature. 366:643-654.
17. cis contributes to malignant tumor growth in von Recklinghausen (type-1) neurofibromatosis. Cell. 69:265-273.
18. Basu, T.N., et al. 1992 Aberrant regulation of ras proteins in malignant tumour cells from type-1 neurofibromatosis patients. Nature. 356:713-715.
19. Guha, A., et al. 1996. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene. 12:507-513.
20. Jacks, T., et al. 1994. Tumor predisposition in mice heterozygous for a targeted mutation in NF1. Nat. Genet. 7:353-361.
21. Brannan, C.I., et al. 1994. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev. 8:1019-1029.
22. cis, inhibition of cell proliferation and morphological changes. Oncogene. 11:325-335.
23. Kim, H.A., Ling, B., and Ratner, N. 1997. NF1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl transferase. Mol. Cell. Biol. 177:862-872.
24. Levi, A.D., et al. 1915. The influence of heregulins on human Schwann cell proliferation. J. Neurosci. 15:1329-1340.
25. Pinkas-Kramarski, R., Alroy, I., and Yarden, Y. 1997. ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling. J. Mammary Gland Biol. Neoplasia. 2:97-107.
26. Burden, S., and Yarden, Y. 1997. Neuregulins and their receptors: a versatile signaling molecule in organogenesis and oncogenesis. Neuron. 18:847-855.
27. Kim, H., DeClue, J.E., and Ratner, N. 1997. cAMP-dependent protein kinase A is required for Schwann cell growth: interaction between cAMP and neuregulin/tyrosine kinase pathways. J. Neurosci. Res 49:236-247.
28. Colman, S.D., Williams, C.A , and Wallace, M.R. 1995. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat. Genet. 11:90-92.
29. Sawada, S., et al. 1996. Identification of NF1 mutations in both alleles of a dermal neurofibroma. Nat. Genet. 14:110-112.
30. Serra, P., et al. 1997. Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. Am. J. Hum. Genet. 61:512-519.
31. Menon, A.G., et al. 1990. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc. Natl. Acad. Sci. USA, 87:5435-5439
32. Velu, T.J., et al. 1989. Retroviruses expressing different levels of the normal epidermal growth factor receptor: biological properties and new bioassay. J. Cell. Biochem. 39:153-166.
33. Gutmann, D.H., et al. 1997. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 278:51-57.
34. Dahlberg, W.K., Little, J.B., Fletcher, J.A., Suit, H.D., and Okunieff, P. 1993. Radiosensitivity in vitro of human soft tissue sarcoma cell lines and skin fibroblasts derived from the same patients. Int. J. Radiat. Biol. 63:191-198.
35. Merlino, G.T., et al. 1985. Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells. Mol. Cell. Biol. 5:1722-1734.
36. Merlino, G.T., et al. 1984. Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science. 224:417-419.
37. Pfeiffer, S.E., and Wechsler, W. 1972. Biochemically differentiated neoplastic clone of Schwann cells. Proc. Natl. Acad. Sci. USA. 69:2885-2889.
38. L. Cancer Res. 56:3666-3669.
39. Levitzki, A., and Gazit, A. 1995. Tyrosine kinase inhibition: an approach to drug development. Science. 267:1782-1788.
40. Garcia, A.M., Rowell, C., Ackermann, K., Kowalczyk, J.J., and Lewis, M.D. 1993. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J. Biol. Chem. 268:18415-18418.
41. Yan, N., et al. 1995. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype. Cancer Res. 55:3569-3575.
42. Salomon, D.S., Brandt, R., Ciardiello, F., and Normanno, N. 1995. Epidermal growth factor-relared peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19:183-232.
43. Bridges, A.J. 1996. The epidermal growth factor receptor family of tyrosine kinases and cancer: can an atypical exemplar be a sound therapeutic target? Curr. Med Chem. 3:167-194.
44. Cichowski, K., et al. 1999. Mouse models of tumor development in neurofibromatosis type 1. Science. 286:2172-2176.
45. Vogel, K.S., et al. 1999. Mouse model for neurofibromatosis type 1. Science. 286:2176-2179.
46. Sturgis, E.M., Woll, S.S., Aydin, F., Marroji, A.J., and Amedee, R.G. 1996. Epidermal growth factor receptor expression by acoustic neuromas. Laryngoscope. 106:457-462.